Concentra Boosts 2026 Outlook After Strong Q1 Growth

Event summary

Concentra reported Q1 2026 revenue of $569.6M, up 13.7% YoY.
Net income rose 28.7% YoY to $52.3M, with adjusted EBITDA up 17.6% to $120.7M.
Patient visits increased 6.7% YoY to 3.4M, with revenue per visit up 3.1% to $151.47.
Company raised FY 2026 guidance, targeting revenue of $2.275B–$2.375B and adjusted EBITDA of $460M–$480M.
Declared a $0.0625 per share dividend, payable June 9, 2026.

The big picture

Concentra's strong Q1 2026 performance underscores its leadership in occupational health services, driven by rising patient volumes and operational efficiencies. The company's raised guidance reflects confidence in its strategic initiatives, including the expansion of its clinic network and the transition to independence from Select Medical Corporation. As the largest provider in the U.S., Concentra's ability to capitalize on workforce health trends will be critical in maintaining its market position.

What we're watching

Execution Risk: Whether Concentra can sustain its growth momentum while completing its transition from Select Medical Corporation.
Market Positioning: How the company's expansion of de novo and acquired occupational health centers will impact its competitive standing.
Financial Discipline: The pace at which Concentra reduces its net leverage ratio below 3.0x while maintaining capital expenditures and shareholder returns.